Suppr超能文献

原发性硬化性胆管炎活体供肝肝移植的当前趋势。

Current trends in living donor liver transplantation for primary sclerosing cholangitis.

机构信息

Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Transplantation. 2011 May 27;91(10):1148-52. doi: 10.1097/TP.0b013e31821694b3.

Abstract

BACKGROUND

Use of the Model for End-Stage Liver Disease (MELD) score has improved the efficiency of allocating deceased donor organs for liver transplant. However, its use may reduce access to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the MELD score variables. To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently.

METHODS

To test this hypothesis, we examined patients in the United Network for Organ Sharing database from December 1, 1994, to May 31, 2009.

RESULTS

In multivariable models conditioned on transplant center, patients with PSC were significantly more likely to receive a living donor transplant in both the pre-MELD (odds ratio [OR]=2.75; 95% confidence interval [CI], 2.20-3.44) and post-MELD eras (OR=4.08; 95% CI, 3.45-4.82). There was a significant interaction between PSC and post-MELD era of transplantation (OR=1.48; 95% CI, 1.11-1.97), indicating that patients with PSC were more likely to receive living donor transplants at baseline relative to patients without PSC, and that this effect was magnified following the introduction of the MELD score.

CONCLUSIONS

These findings raise the possibility that allocating livers on the basis of MELD score may have yielded the unintended consequence of increasing rates for living donor transplants for patients with PSC relative to patients with other forms of end-stage liver disease. Future research is needed to determine whether the practice of selectively transplanting patients with PSC with living donor transplants is associated with differences in clinical outcomes.

摘要

背景

使用终末期肝病模型(MELD)评分提高了分配已故供体器官进行肝移植的效率。然而,由于 MELD 评分变量的权重,其使用可能会减少原发性硬化性胆管炎(PSC)患者获得已故供体肝脏的机会。为了克服 MELD 时代后的这些障碍,临床医生可能会更频繁地将 PSC 患者与无 PSC 患者相比,推荐他们进行活体供体移植。

方法

为了验证这一假设,我们检查了 1994 年 12 月 1 日至 2009 年 5 月 31 日期间美国器官共享网络数据库中的患者。

结果

在基于移植中心的多变量模型中,PSC 患者在 MELD 前(优势比 [OR]=2.75;95%置信区间 [CI],2.20-3.44)和 MELD 后(OR=4.08;95% CI,3.45-4.82)时代更有可能接受活体供体移植。PSC 和移植后 MELD 时代之间存在显著的相互作用(OR=1.48;95% CI,1.11-1.97),这表明与无 PSC 患者相比,PSC 患者更有可能在基线时接受活体供体移植,并且在 MELD 评分引入后,这种效果更加明显。

结论

这些发现提出了一种可能性,即根据 MELD 评分分配肝脏可能产生了意想不到的后果,即与其他形式的终末期肝病患者相比,PSC 患者接受活体供体移植的比率增加。需要进一步研究来确定选择性对 PSC 患者进行活体供体移植的做法是否与临床结果的差异有关。

相似文献

1
Current trends in living donor liver transplantation for primary sclerosing cholangitis.
Transplantation. 2011 May 27;91(10):1148-52. doi: 10.1097/TP.0b013e31821694b3.
3
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.
Hepatol Commun. 2023 Aug 3;7(8). doi: 10.1097/HC9.0000000000000219. eCollection 2023 Aug 1.
6
Modifiable patient characteristics and racial disparities in evaluation completion and living donor transplant.
Clin J Am Soc Nephrol. 2013 Jun;8(6):995-1002. doi: 10.2215/CJN.08880812. Epub 2013 Mar 21.
7
Disparities in liver transplantation before and after introduction of the MELD score.
JAMA. 2008 Nov 26;300(20):2371-8. doi: 10.1001/jama.2008.720.
8
Sex Disparity in Liver Transplant and Access to Living Donation.
JAMA Surg. 2021 Nov 1;156(11):1010-1017. doi: 10.1001/jamasurg.2021.3586.
9
Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era.
Langenbecks Arch Surg. 2014 Dec;399(8):1021-9. doi: 10.1007/s00423-014-1214-6. Epub 2014 Jun 4.
10
Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
J Hepatol. 2017 Nov;67(5):957-965. doi: 10.1016/j.jhep.2017.06.027. Epub 2017 Jul 8.

引用本文的文献

1
Machine Learning Prediction Model of Waitlist Outcomes in Patients with Primary Sclerosing Cholangitis.
Transplant Direct. 2025 Mar 28;11(4):e1774. doi: 10.1097/TXD.0000000000001774. eCollection 2025 Apr.
2
Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis.
Hepatol Int. 2025 Feb;19(1):244-255. doi: 10.1007/s12072-024-10733-y. Epub 2024 Oct 30.
6
Treatment of primary sclerosing cholangitis in children.
World J Hepatol. 2019 Jan 27;11(1):19-36. doi: 10.4254/wjh.v11.i1.19.
8
Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway.
Transplant Direct. 2015 Oct 19;1(9):e39. doi: 10.1097/TXD.0000000000000548. eCollection 2015 Oct.
10
Liver Transplant in Patients With Primary Sclerosing Cholangitis.
Gastroenterol Hepatol (N Y). 2016 Feb;12(2):127-9.

本文引用的文献

1
Liver transplantation for cholangiocarcinoma.
Transpl Int. 2010 Jul;23(7):692-7. doi: 10.1111/j.1432-2277.2010.01108.x. Epub 2010 May 20.
3
Re-weighting the model for end-stage liver disease score components.
Gastroenterology. 2008 Nov;135(5):1575-81. doi: 10.1053/j.gastro.2008.08.004. Epub 2008 Aug 15.
4
Analysis of longitudinal data to evaluate a policy change.
Stat Med. 2008 Oct 30;27(24):5005-25. doi: 10.1002/sim.3340.
5
Improvement in survival associated with adult-to-adult living donor liver transplantation.
Gastroenterology. 2007 Dec;133(6):1806-13. doi: 10.1053/j.gastro.2007.09.004. Epub 2007 Sep 14.
8
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.
Am J Gastroenterol. 2004 Mar;99(3):523-6. doi: 10.1111/j.1572-0241.2004.04067.x.
9
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.
Gastroenterology. 2003 Nov;125(5):1364-9. doi: 10.1016/j.gastro.2003.07.011.
10
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
J Hepatol. 2002 Mar;36(3):321-7. doi: 10.1016/s0168-8278(01)00288-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验